|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNRNP35 |
Gene summary for SNRNP35 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNRNP35 | Gene ID | 11066 |
| Gene name | small nuclear ribonucleoprotein U11/U12 subunit 35 | |
| Gene Alias | HM-1 | |
| Cytomap | 12q24.31 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024RBU2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11066 | SNRNP35 | LZE4T | Human | Esophagus | ESCC | 1.47e-03 | 1.13e-01 | 0.0811 |
| 11066 | SNRNP35 | LZE5T | Human | Esophagus | ESCC | 4.10e-03 | 1.82e-01 | 0.0514 |
| 11066 | SNRNP35 | LZE7T | Human | Esophagus | ESCC | 4.61e-05 | 2.98e-01 | 0.0667 |
| 11066 | SNRNP35 | LZE8T | Human | Esophagus | ESCC | 1.17e-02 | 6.34e-02 | 0.067 |
| 11066 | SNRNP35 | LZE20T | Human | Esophagus | ESCC | 1.10e-04 | 1.60e-01 | 0.0662 |
| 11066 | SNRNP35 | LZE22T | Human | Esophagus | ESCC | 3.16e-02 | 1.53e-01 | 0.068 |
| 11066 | SNRNP35 | LZE24T | Human | Esophagus | ESCC | 1.30e-10 | 2.73e-01 | 0.0596 |
| 11066 | SNRNP35 | LZE21T | Human | Esophagus | ESCC | 7.48e-03 | 1.84e-01 | 0.0655 |
| 11066 | SNRNP35 | LZE6T | Human | Esophagus | ESCC | 6.23e-09 | 3.13e-01 | 0.0845 |
| 11066 | SNRNP35 | P2T-E | Human | Esophagus | ESCC | 3.81e-34 | 5.69e-01 | 0.1177 |
| 11066 | SNRNP35 | P4T-E | Human | Esophagus | ESCC | 1.15e-19 | 3.84e-01 | 0.1323 |
| 11066 | SNRNP35 | P5T-E | Human | Esophagus | ESCC | 3.53e-14 | 2.13e-01 | 0.1327 |
| 11066 | SNRNP35 | P8T-E | Human | Esophagus | ESCC | 3.77e-18 | 3.07e-01 | 0.0889 |
| 11066 | SNRNP35 | P9T-E | Human | Esophagus | ESCC | 4.04e-11 | 2.27e-01 | 0.1131 |
| 11066 | SNRNP35 | P10T-E | Human | Esophagus | ESCC | 2.18e-21 | 4.50e-01 | 0.116 |
| 11066 | SNRNP35 | P11T-E | Human | Esophagus | ESCC | 6.46e-10 | 3.33e-01 | 0.1426 |
| 11066 | SNRNP35 | P12T-E | Human | Esophagus | ESCC | 8.82e-20 | 3.05e-01 | 0.1122 |
| 11066 | SNRNP35 | P15T-E | Human | Esophagus | ESCC | 1.52e-14 | 2.41e-01 | 0.1149 |
| 11066 | SNRNP35 | P16T-E | Human | Esophagus | ESCC | 7.76e-16 | 3.12e-01 | 0.1153 |
| 11066 | SNRNP35 | P17T-E | Human | Esophagus | ESCC | 9.31e-06 | 3.03e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
| GO:0000375112 | Skin | cSCC | RNA splicing, via transesterification reactions | 201/4864 | 324/18723 | 4.07e-43 | 5.10e-40 | 201 |
| GO:0000377112 | Skin | cSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0000398112 | Skin | cSCC | mRNA splicing, via spliceosome | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNRNP35 | SNV | Missense_Mutation | c.369N>A | p.Asp123Glu | p.D123E | Q16560 | protein_coding | deleterious(0.04) | benign(0.227) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| SNRNP35 | SNV | Missense_Mutation | c.32N>A | p.Pro11His | p.P11H | Q16560 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SNRNP35 | SNV | Missense_Mutation | c.535G>A | p.Asp179Asn | p.D179N | Q16560 | protein_coding | deleterious(0) | benign(0.139) | TCGA-AZ-6607-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| SNRNP35 | deletion | Frame_Shift_Del | c.453delN | p.Lys153ArgfsTer6 | p.K153Rfs*6 | Q16560 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
| SNRNP35 | deletion | In_Frame_Del | c.313_315delAAG | p.Lys105del | p.K105del | Q16560 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| SNRNP35 | SNV | Missense_Mutation | novel | c.487N>T | p.Arg163Trp | p.R163W | Q16560 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| SNRNP35 | SNV | Missense_Mutation | c.298N>A | p.Ala100Thr | p.A100T | Q16560 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| SNRNP35 | SNV | Missense_Mutation | novel | c.134N>C | p.Val45Ala | p.V45A | Q16560 | protein_coding | tolerated(0.67) | benign(0.048) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SNRNP35 | SNV | Missense_Mutation | c.679G>A | p.Asp227Asn | p.D227N | Q16560 | protein_coding | tolerated_low_confidence(0.09) | benign(0.023) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SNRNP35 | SNV | Missense_Mutation | c.535N>A | p.Asp179Asn | p.D179N | Q16560 | protein_coding | deleterious(0) | benign(0.139) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |